With AbbVie and Allergan working out the fine print of their $63 billion merger, the future of Allergan's aesthetics business has been a sticking point for analysts worried about a drag on the new company's bottom line. In response, AbbVie came up with a solution: Just keep the aesthetics business separate.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,